Aldeyra Therapeutics Inc Provide Results from the Phase 3 Invigorate Clinical Trial Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Conference Call. (Operator Instructions) I would now like to turn the conference over to your Chief Financial Officer, Joshua Reed. Please go ahead, sir.
Good morning, everyone. With me is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This morning, we issued a news release reporting top line results from the Phase III INVIGORATE clinical trial of reproxalap in allergic conjunctivitis. A copy of the news release is available on the Investors & Media section of our website, www.aldeyra.com.
The news release should be read and considered in conjunction with the slides presented and prepared comments made on today's call.
Please turn to Slide 2. This presentation and various remarks, which may be made during this presentation contain forward-looking statements regarding Aldeyra and investigational drug candidate reproxalap.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |